このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Bicycle Therapeutics マネジメント
マネジメント 基準チェック /44
Bicycle Therapeutics'の CEO はKevin Leeで、 Sep2015年に任命され、 の在任期間は 8.75年です。 の年間総報酬は$ 5.54Mで、 12.8%給与と87.2%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.33%を直接所有しており、その価値は$ 4.67M 。経営陣と取締役会の平均在任期間はそれぞれ2.4年と4.9年です。
主要情報
Kevin Lee
最高経営責任者
US$5.5m
報酬総額
| CEO給与比率 | 12.8% |
| CEO在任期間 | 8.8yrs |
| CEOの所有権 | 0.3% |
| 経営陣の平均在職期間 | 2.4yrs |
| 取締役会の平均在任期間 | 4.9yrs |
経営陣の近況
Recent updates
Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10
Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Bicycle Therapeutics EPS misses by $0.05, beats on revenue
May 06Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates
Mar 08Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Feb 23CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$168m |
| Dec 31 2023 | US$6m | US$710k | -US$181m |
| Sep 30 2023 | n/a | n/a | -US$162m |
| Jun 30 2023 | n/a | n/a | -US$140m |
| Mar 31 2023 | n/a | n/a | -US$124m |
| Dec 31 2022 | US$9m | US$673k | -US$113m |
| Sep 30 2022 | n/a | n/a | -US$101m |
| Jun 30 2022 | n/a | n/a | -US$87m |
| Mar 31 2022 | n/a | n/a | -US$78m |
| Dec 31 2021 | US$4m | US$677k | -US$67m |
| Sep 30 2021 | n/a | n/a | -US$66m |
| Jun 30 2021 | n/a | n/a | -US$62m |
| Mar 31 2021 | n/a | n/a | -US$56m |
| Dec 31 2020 | US$3m | US$592k | -US$51m |
| Sep 30 2020 | n/a | n/a | -US$38m |
| Jun 30 2020 | n/a | n/a | -US$37m |
| Mar 31 2020 | n/a | n/a | -US$35m |
| Dec 31 2019 | US$4m | US$517k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$33m |
| Jun 30 2019 | n/a | n/a | -US$31m |
| Mar 31 2019 | n/a | n/a | -US$26m |
| Dec 31 2018 | US$818k | US$386k | -US$22m |
報酬と市場: Kevinの 総報酬 ($USD 5.54M ) は、 US市場 ($USD 5.66M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Kevinの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Kevin Lee (56 yo)
8.8yrs
在職期間
US$5,540,400
報酬
Dr. Kevin Lee, M.B.A., Ph D., has been Chief Executive Officer of Bicycle Therapeutics plc since September 2015. Dr. Lee joined Bicycle Therapeutics from Pfizer where he served as Senior Vice President and...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Executive Director | 8.8yrs | US$5.54m | 0.33% $ 4.6m | |
| Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.4m | |
| Chief Financial Officer | less than a year | US$2.88m | データなし | |
| Chief Development Officer | 1.3yrs | US$2.82m | 0% $ 0 | |
| Scientific Founder | no data | データなし | データなし | |
| Chief Operating Officer | 2.4yrs | US$5.98m | 0.021% $ 301.0k | |
| Senior VP | less than a year | データなし | 0.0026% $ 37.4k | |
| Chief Technology Officer | 2.4yrs | US$3.07m | 0.070% $ 992.3k | |
| Chief Scientific Officer | 7.4yrs | データなし | 0.034% $ 477.0k | |
| General Counsel | 4.2yrs | データなし | データなし | |
| Senior Vice President of Capital Markets & Corporate Communications | no data | データなし | データなし | |
| Head of Clinical and Project Management | 8.1yrs | データなし | データなし |
2.4yrs
平均在職期間
56yo
平均年齢
経験豊富な経営陣: BCYCの経営陣は 経験豊富 であると考えられます ( 2.4年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Executive Director | 8.8yrs | US$5.54m | 0.33% $ 4.6m | |
| Co-Founder & Non-Executive Director | no data | US$477.04k | 0.24% $ 3.4m | |
| Chairman of Scientific Advisory Board | 6.1yrs | データなし | データなし | |
| Non-Executive Chairman | 5.3yrs | US$1.06m | 0.031% $ 441.8k | |
| Independent Non-Executive Director | 3.3yrs | US$482.29k | 0.016% $ 220.9k | |
| Independent Non-Executive Director | 4.9yrs | US$526.91k | 0.016% $ 220.9k | |
| Member of Scientific Advisory Board | 3.7yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 3.7yrs | データなし | データなし | |
| Independent Non-Executive Director | 4.9yrs | US$495.41k | 0.016% $ 220.9k | |
| Member of Scientific Advisory Board | 6.1yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 3.7yrs | データなし | データなし | |
| Member of Scientific Advisory Board | 3.7yrs | データなし | データなし |
4.9yrs
平均在職期間
64yo
平均年齢
経験豊富なボード: BCYCの 取締役会 は 経験豊富 であると考えられます ( 4.9年の平均在任期間)。